TERN Terns Pharmaceuticals

Terns Pharmaceuticals to Participate in Upcoming September Investor Conferences

Terns Pharmaceuticals to Participate in Upcoming September Investor Conferences

FOSTER CITY, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, non-alcoholic steatohepatitis (NASH) and obesity, today announced that members of senior management will be participating in the following upcoming investor conferences in September.

2023 Wells Fargo Healthcare Conference

Location: Encore Boston Harbor, Boston, MA

Format: 1x1 Investor Meetings on Thursday, September 7

H.C. Wainwright 25th Annual Global Investment Conference

Location: Lotte New York Palace Hotel, New York, NY

Format: Fireside Chat on Monday, September 11 at 11:30am ET

A live webcast of the Fireside Chat will be available on the investor relations page of the Terns Pharmaceuticals website at . A replay of the webcasts will be archived on Terns’ website for at least 30 days following the presentations.

About Terns Pharmaceuticals

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, NASH and obesity. Terns’ pipeline includes two clinical stage development programs including an allosteric BCR-ABL inhibitor and a THR-β agonist (+/- an FXR agonist), and preclinical small-molecule GLP-1 receptor agonist and GIPR modulator programs. For more information, please visit: .

Contacts for Terns

Investors

Mark Vignola

Media

Jenna Urban

Berry & Company Public Relations



EN
05/09/2023

Underlying

TERNTerns Pharmaceuticals

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Terns Pharmaceuticals

 PRESS RELEASE
Free
TERN Terns Pharmaceu...

Terns Pharmaceuticals Reports Topline 12-week Data from its Phase 2 Tr...

Terns Pharmaceuticals Reports Topline 12-week Data from its Phase 2 Trial Evaluating Oral GLP-1 Receptor Agonist TERN-601 in Obesity Results show maximum placebo-adjusted weight loss of 4.6% with 12% treatment discontinuation due to adverse events Asymptomatic, reversible grade 3 liver enzyme elevations occurred in three participants during post-treatment follow-up period, two of which were deemed drug related Company will not advance TERN-601 or invest in other metabolic assets Reiterates focus on TERN-701, a potential best-in-class allosteric BCR-ABL inhibitor, for chronic myeloid leuk...

October 21, 2025 1 EN
 PRESS RELEASE
Free
TERN Terns Pharmaceu...

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under...

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) FOSTER CITY, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that it has granted as of October 1, 2025 equity inducement awards to four new employees under the terms of the 2022 Employment Inducement Award Plan, as amended. The equity awards were a...

October 2, 2025 1 EN
 PRESS RELEASE
Free
TERN Terns Pharmaceu...

Terns Pharmaceuticals to Host an Educational Webinar on TERN-701 for I...

Terns Pharmaceuticals to Host an Educational Webinar on TERN-701 for Investors in Advance of Phase 1 Data Expected in Fourth Quarter 2025 Webinar to be held on Wednesday, September 3, 2025 at 4:30 p.m. ET FOSTER CITY, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced it will host an investor educational webinar on TERN-701 in advance of the data re...

August 21, 2025 1 EN
 PRESS RELEASE
Free
TERN Terns Pharmaceu...

Terns Pharmaceuticals Reports Second Quarter 2025 Financial Results an...

Terns Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Updates Phase 1 trial of TERN-701 in chronic myeloid leukemia (CML) enrolling well; efficacy and safety data including 6-month major molecular response (MMR) rates expected in 4Q25 Phase 2 trial of TERN-601 for obesity completed enrollment; 12-week efficacy, safety and tolerability data expected in early 4Q25 Cash runway into 2028 focused on advancing CML program internally and partnering metabolic assets Terns to host a TERN-701-focused educational webinar in September 2025 FOSTER CITY,...

August 5, 2025 1 EN
 PRESS RELEASE
Free
TERN Terns Pharmaceu...

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under...

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) FOSTER CITY, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that it has granted as of August 1, 2025 equity inducement awards to two new employees under the terms of the 2022 Employment Inducement Award Plan, as amended. The equity awards were app...

August 4, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch